title: Pharmacotherapy of obesity: targets and perspectives.
abstract: The search for anti-obesity agents has become one of the most exciting areas in drug discovery. Subsequent to an enormous increase in the number of possible molecular targets, the focus has shifted from target identification to target validation. Because important biological functions such as the regulation of energy intake and expenditure are controlled by complex systems, an improved understanding of pathophysiology is a prerequisite for the selection of successful development candidates for the treatment of obesity. Although most of the information on the regulation of energy balance has been obtained from rodents, various monogenic forms of human obesity provide clinical proof of concept for some of these mechanisms. However, it is still not known which are the most promising clinical approaches to lowering body weight and subsequently reducing morbidity and mortality.
authors.affiliation: Cardiovascular and Metabolic Diseases Research, Novartis Pharma AG, CH 4002 Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Chiesi
authors.forename: C
authors.initials: C
authors.lastname: Huppertz
authors.forename: K G
authors.initials: KG
authors.lastname: Hofbauer
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D009765:Obesity / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants